1	State of Arkansas	A Bill	
2	93rd General Assembly	A DIII	HOUSE BILL 1247
3	Regular Session, 2021		HOUSE BILL 124/
4 5	By: Representative Gonzal	ag	
6	by. Representative Gonzan	55	
7		For An Act To Be Entitled	
8	AN ACT T	O MODIFY PHYSICIAN DISPENSING; TO ALLO	W
9		ON OF PHYSICIAN DISPENSING; AND FOR OT	
10	PURPOSES	· ·	
11			
12			
13		Subtitle	
14	TO	MODIFY PHYSICIAN DISPENSING; AND TO	
15	ALI	OW DELEGATION OF PHYSICIAN DISPENSING.	
16			
17			
18	BE IT ENACTED BY THE	GENERAL ASSEMBLY OF THE STATE OF ARKA	NSAS:
19			
20	SECTION 1. Ar	kansas Code § 17-95-102 is amended to	read as follows:
21	17-95-102. <del>Le</del>	<del>gend</del> <u>Physician dispensing of</u> drugs <u>in</u>	Schedules III-V.
22	(a) <del>A dispens</del>	<del>ing physician is</del> <u>As used in this secti</u>	on, a "dispensing
23	physician" means a p	hysician licensed under the Arkansas M	edical Practices
24	Act, § 17-95-201 et	seq.,  17-95-301 et seq., and  17-95	-401 et seq., who
25	purchases <del>legend</del> dru	gs <u>in Schedules III-V</u> to be dispensed	to his or her
26	patients for the pat	ients' personal use and administration	outside the
27	physician's office.		
28		ion <del>shall</del> <u>does</u> not apply to physicians	-
29	drugs in injectable	form unless they are controlled substan	nces, in which case
30	the section shall fu		
31	_	nsing physician shall:	
32		sonally dispense <del>legend</del> drugs <u>in Sched</u>	
33		rugs <u>in Schedules III-V</u> may <del>not</del> be del	
34		Keep records of all receipts and distr	ibutions of <del>legend</del>
35	drugs <u>in Schedules I</u>		
36	<u>(B</u>	<u>)</u> The records shall be subject to insp	pection by the

1	proper enforcement authority and shall be readily accessible for inspection		
2	and maintained in a central registry; and		
3	(3) Label $\frac{1}{1}$ Label $\frac{1}{1}$ drugs $\frac{1}{1}$ Schedules III-V with the following		
4	information:		
5	(A) Patient's name and address;		
6	(B) Prescribing physician's address and narcotic registry		
7	number issued by the United States Drug Enforcement Administration;		
8	(C) Date of dispensing; and		
9	(D) Directions and cautionary statements, if any, as		
10	required by law.		
11	(d)(1) A physician licensed under the Arkansas Medical Practices Act,		
12	§ 17-95-201 et seq., § 17-95-301 et seq., and § 17-95-401 et seq., shall not		
13	dispense legend drugs without prior approval by the Arkansas State Medical		
14	Board after application to the board and on the showing of need.		
15	(2) Licensed physicians who were dispensing in the ordinary		
16	course of their practice before April 12, 2013, shall be exempt from the		
17	requirements of this subsection.		
18	(3) The board shall determine whether need exists for a		
19	physician to dispense a specific legend drug to the physician's patient for a		
20	patient's personal use and administration outside of the physician's office		
21	based on such information as is necessary for the board to determine:		
22	(A) The legend drug or drugs that the physician requests		
23	to dispense;		
24	(B) The ability of a physician's patient to obtain the		
25	legend drug from other medical professionals;		
26	(C) The availability of the legend drug to be prescribed		
27	<del>by the physician;</del>		
28	(D) The hours at which the legend drug may be obtained		
29	from other medical professionals;		
30	(E) The distance the physician's patient must travel to		
31	obtain the legend drug from other medical professionals;		
32	(F) Whether the physician has been investigated by the		
33	board concerning the improper prescribing or use of a legend drug;		
34	(G) Whether the physician has a financial relationship		
35	with the manufacturer of a legend drug that would create the appearance of a		
36	conflict of interest:		

1	<del>(n) whether the physician dispensing a legend drug will</del>
2	foster cost containment through improved efficiency and productivity; and
3	(I) The procedures the physician has implemented to:
4	(i) Assure compliance with the requirements of
5	subsection (c) of this section;
6	(ii) Monitor and guard against potential drug
7	interactions;
8	(iii) Store and safeguard the legend drugs; and
9	(iv) Comply with the Prescription Drug Monitoring
10	Program Act, § 20-7-601 et seq., concerning the reporting requirements to th
11	Prescription Drug Monitoring Program.
12	(4)(d) A prescription for a topical medication, Naloxone,
13	nicotine replacement therapy products, or contraceptives is exempt from
14	subdivision $(d)(3)$ of this section.
15	(e) The <del>board</del> <u>Arkansas State Medical Board</u> shall enforce the
16	provisions of this section and is authorized and directed to adopt rules to
17	carry out its purpose the purpose of this section.
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	